vs
CARLISLE COMPANIES INC（CSL）与爱德华生命科学（EW）财务数据对比。点击上方公司名可切换其他公司
爱德华生命科学的季度营收约是CARLISLE COMPANIES INC的1.6倍（$1.6B vs $1.1B），爱德华生命科学净利率更高（23.1% vs 12.1%，领先11.0%），爱德华生命科学同比增速更快（16.7% vs -4.0%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs -14.8%）
卡莱尔公司是专业建筑产品供应商，聚焦于提升建筑能效与稳固性，面向商业建筑领域生产销售单层屋面产品、质保系统及配套配件，旗下设有卡莱尔建筑材料、卡莱尔防水技术两大业务板块，产品涵盖防潮材料、屋面防护层等多个品类。
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
CSL vs EW — 直观对比
营收规模更大
EW
是对方的1.6倍
$1.1B
营收增速更快
EW
高出20.7%
-4.0%
净利率更高
EW
高出11.0%
12.1%
两年增速更快
EW
近两年复合增速
-14.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.6B |
| 净利润 | $127.7M | $380.7M |
| 毛利率 | 34.5% | 78.0% |
| 营业利润率 | 17.1% | 1.8% |
| 净利率 | 12.1% | 23.1% |
| 营收同比 | -4.0% | 16.7% |
| 净利润同比 | -10.9% | 6.8% |
| 每股收益（稀释后） | $3.10 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSLEW
| Q1 26 | $1.1B | $1.6B | ||
| Q4 25 | $1.1B | $1.6B | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.1B | $1.4B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $1.5B | $1.4B |
净利润CSLEW
| Q1 26 | $127.7M | $380.7M | ||
| Q4 25 | $127.4M | $91.2M | ||
| Q3 25 | $214.2M | $291.1M | ||
| Q2 25 | $255.8M | $333.2M | ||
| Q1 25 | $143.3M | $358.0M | ||
| Q4 24 | $162.8M | $385.6M | ||
| Q3 24 | $244.3M | $3.1B | ||
| Q2 24 | $712.4M | $366.3M |
毛利率CSLEW
| Q1 26 | 34.5% | 78.0% | ||
| Q4 25 | 33.8% | 78.1% | ||
| Q3 25 | 36.0% | 77.8% | ||
| Q2 25 | 37.3% | 77.5% | ||
| Q1 25 | 35.2% | 78.7% | ||
| Q4 24 | 36.1% | 78.9% | ||
| Q3 24 | 38.6% | 80.6% | ||
| Q2 24 | 39.2% | 79.9% |
营业利润率CSLEW
| Q1 26 | 17.1% | 1.8% | ||
| Q4 25 | 16.8% | 9.6% | ||
| Q3 25 | 21.8% | 19.8% | ||
| Q2 25 | 23.1% | 26.8% | ||
| Q1 25 | 16.8% | 27.9% | ||
| Q4 24 | 19.9% | 22.6% | ||
| Q3 24 | 23.7% | 25.9% | ||
| Q2 24 | 26.0% | 26.8% |
净利率CSLEW
| Q1 26 | 12.1% | 23.1% | ||
| Q4 25 | 11.3% | 5.8% | ||
| Q3 25 | 15.9% | 18.7% | ||
| Q2 25 | 17.6% | 21.7% | ||
| Q1 25 | 13.1% | 25.3% | ||
| Q4 24 | 14.5% | 27.8% | ||
| Q3 24 | 18.3% | 226.7% | ||
| Q2 24 | 49.1% | 26.7% |
每股收益（稀释后）CSLEW
| Q1 26 | $3.10 | $0.66 | ||
| Q4 25 | $3.06 | $0.16 | ||
| Q3 25 | $4.98 | $0.50 | ||
| Q2 25 | $5.88 | $0.56 | ||
| Q1 25 | $3.20 | $0.61 | ||
| Q4 24 | $3.76 | $0.65 | ||
| Q3 24 | $5.25 | $5.13 | ||
| Q2 24 | $14.84 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $771.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7B | — |
| 总资产 | — | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSLEW
| Q1 26 | $771.3M | — | ||
| Q4 25 | $1.1B | $4.2B | ||
| Q3 25 | $1.1B | $3.8B | ||
| Q2 25 | $68.4M | $4.1B | ||
| Q1 25 | $220.2M | $3.9B | ||
| Q4 24 | $753.5M | $4.0B | ||
| Q3 24 | $1.5B | $4.4B | ||
| Q2 24 | $1.7B | $2.0B |
总债务CSLEW
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
股东权益CSLEW
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.8B | $10.3B | ||
| Q3 25 | $2.0B | $10.2B | ||
| Q2 25 | $2.1B | $10.5B | ||
| Q1 25 | $2.2B | $10.1B | ||
| Q4 24 | $2.5B | $10.0B | ||
| Q3 24 | $2.8B | $9.5B | ||
| Q2 24 | $3.0B | $7.4B |
总资产CSLEW
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $13.7B | ||
| Q3 25 | $6.5B | $13.3B | ||
| Q2 25 | $5.5B | $13.5B | ||
| Q1 25 | $5.5B | $13.0B | ||
| Q4 24 | $5.8B | $13.1B | ||
| Q3 24 | $6.5B | $13.0B | ||
| Q2 24 | $6.7B | $10.1B |
负债/权益比CSLEW
| Q1 26 | — | — | ||
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.45× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | — |
| 自由现金流率自由现金流/营收 | -6.9% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $924.8M | — |
8季度趋势，按日历期对齐
经营现金流CSLEW
| Q1 26 | — | — | ||
| Q4 25 | $386.0M | $450.9M | ||
| Q3 25 | $426.9M | $573.7M | ||
| Q2 25 | $287.1M | $290.2M | ||
| Q1 25 | $1.8M | $280.4M | ||
| Q4 24 | $370.6M | $-127.5M | ||
| Q3 24 | $312.8M | $351.8M | ||
| Q2 24 | $183.4M | $371.5M |
自由现金流CSLEW
| Q1 26 | $-73.0M | — | ||
| Q4 25 | $346.1M | $353.5M | ||
| Q3 25 | $393.4M | $516.2M | ||
| Q2 25 | $258.3M | $240.9M | ||
| Q1 25 | $-27.2M | $224.4M | ||
| Q4 24 | $334.0M | $-177.3M | ||
| Q3 24 | $293.5M | $299.9M | ||
| Q2 24 | $158.5M | $286.1M |
自由现金流率CSLEW
| Q1 26 | -6.9% | — | ||
| Q4 25 | 30.7% | 22.5% | ||
| Q3 25 | 29.2% | 33.2% | ||
| Q2 25 | 17.8% | 15.7% | ||
| Q1 25 | -2.5% | 15.9% | ||
| Q4 24 | 29.7% | -12.8% | ||
| Q3 24 | 22.0% | 22.1% | ||
| Q2 24 | 10.9% | 20.9% |
资本支出强度CSLEW
| Q1 26 | 2.7% | — | ||
| Q4 25 | 3.5% | 6.2% | ||
| Q3 25 | 2.5% | 3.7% | ||
| Q2 25 | 2.0% | 3.2% | ||
| Q1 25 | 2.6% | 4.0% | ||
| Q4 24 | 3.3% | 3.6% | ||
| Q3 24 | 1.4% | 3.8% | ||
| Q2 24 | 1.7% | 6.2% |
现金转化率CSLEW
| Q1 26 | — | — | ||
| Q4 25 | 3.03× | 4.94× | ||
| Q3 25 | 1.99× | 1.97× | ||
| Q2 25 | 1.12× | 0.87× | ||
| Q1 25 | 0.01× | 0.78× | ||
| Q4 24 | 2.28× | -0.33× | ||
| Q3 24 | 1.28× | 0.11× | ||
| Q2 24 | 0.26× | 1.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSL
| CCM | $758.0M | 72% |
| CWT | $294.0M | 28% |
EW
暂无分部数据
